Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$134.97 USD
+1.90 (1.43%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $135.07 +0.10 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 261 - 280 ( 307 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Transferring Coverage and Placing Under Review
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
1Q13 - KINECT and KINECT-II Data Releases in 2H13 Are The Focus
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Former Announcement of the Start of Elagolix in UF Phase IIb Study
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
3Q12 Call Un-eventful with Two NBI-98854 Clinical Data Releases Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J